english.prescrire.org > Prescrire International > N°159 - April 2015

n°159

April 2015

Issue Contents
Editorial

Free  Masthead

p.86

Free  Preconceptions based on drug origin

p.88
Plant-based medicines can be harmful

Marketing Authorisations


Vemurafenib (Zelboraf°) with longer follow-up

p.89-90
Metastatic melanoma: a few extra months of life, but many adverse effects

Dabrafenib (Tafinlar°)

p.90
Metastatic melanoma: a me-too of vemurafenib

Dimethyl fumarate (Tecfidera°)

p.91
Multiple sclerosis: too many long-term unknowns

INN common stem: -rafenib

p.91

Free  Green tea leaf extract (Veregen°)

p.92
An aggressive topical treatment for anogenital warts

SC trastuzumab (Herceptin°)

p.93
Ready to use, but more serious adverse effects than IV trastuzumab

Diacerein

p.94
A controversial EU re-evaluation upholds marketing authorisation, unfortunately

Kaneuron°

p.95
An oral solution of phenobarbital with dangerous packaging

Ipilimumab (Yervoy°) and inoperable or metastatic melanoma

p.96
More evaluation needed, in both first- and second-line use

Adverse Effects


Topical minoxidil: accidental poisoning in children

p.97
Hypotension and persistent tachycardia

Acute kidney injury due to drug-induced hypersensitivity

p.97
Stop medication as soon as possible

Weekly methotrexate: harmful to exposed embryos

p.98
Miscarriages and major malformations

Ambroxol, bromhexine: anaphylactic reactions

p.98
Unfavourable harm-benefit balance

Growth hormone: brain haemorrhage

p.98
Epidemiological study

Reviews


Mammographic breast cancer screening - Part II

p.99-102
Non-randomised comparisons: results similar to those of randomised trials

Identifying the least biased studies

p.102

Hypoglycaemic therapy in type 2 diabetes - Part I

p.103-106
Metformin is the only glucose-lowering drug known to prevent complications of diabetes

Types of glucose-lowering drugs and their mechanisms of action

p.105

Outlook


Free  New drugs and indications in 2014

p.107-110
Some advances this year, but many drugs are poorly evaluated, too expensive or more dangerous than useful

Free  No-gift policy in medical schools

p.111
Demonstrated impact on prescribing behaviour

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe